Um estudo de nipocalimabe ou imunoglobulina intravenosa (IVIG) em gestações com risco de trombocitopenia aloimune fetal e neonatal (FNAIT) (FREESIA-3)
Estudo multicêntrico, aberto e randomizado de nipocalimabe ou imunoglobulina intravenosa (IVIG) em gestações com risco de trombocitopenia aloimune fetal e neonatal (FNAIT)
The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Study Contact
- Número de telefone: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Locais de estudo
-
-
-
Berlin, Alemanha, 10117
- Recrutamento
- Charite Universitaetsmedizin Berlin
-
Giessen, Alemanha, 35392
- Recrutamento
- Universitaetsklinikum Giessen und Marburg GmbH
-
Hanover, Alemanha, 30625
- Recrutamento
- Medizinische Hochschule Hannover
-
Jena, Alemanha, 07747
- Recrutamento
- Universitatsklinikum Jena
-
Tübingen, Alemanha, 72076
- Recrutamento
- Universitaetsklinikum Tuebingen
-
-
-
-
-
Leuven, Bélgica, 3000
- Recrutamento
- Universitair Ziekenhuis Leuven
-
-
-
-
-
Košice, Eslováquia, 040 11
- Recrutamento
- Univerzitna nemocnica L. Pasteura Kosice
-
Nové Zámky, Eslováquia, 940 34
- Recrutamento
- Fakultna nemocnica s poliklinikou Nove Zamky
-
-
-
-
-
Ljubljana, Eslovênia, 1000
- Recrutamento
- Univerzitetni klinicni center Ljubljana
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Recrutamento
- The University of Alabama at Birmingham
-
-
California
-
Sacramento, California, Estados Unidos, 95817
- Recrutamento
- UC Davis School of Medicine
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- Childrens Hospital Colorado
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32611
- Recrutamento
- University of Florida at Shands
-
-
Illinois
-
Park Ridge, Illinois, Estados Unidos, 60068
- Recrutamento
- Advocate Children's Hospital
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Suspenso
- Riley Children s Hospital
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Recrutamento
- University of Iowa Hospital and Clinics
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Recrutamento
- Wayne State University
-
-
New York
-
Rochester, New York, Estados Unidos, 14642
- Recrutamento
- University of Rochester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- Recrutamento
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45267
- Recrutamento
- University of Cincinnati
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Recrutamento
- Oregon Health And Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- Hospital of the University of Pennsylvania
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Recrutamento
- Vanderbilt University Medical Center
-
-
Texas
-
Galveston, Texas, Estados Unidos, 77555
- Recrutamento
- University of Texas Medical Branch
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84108
- Recrutamento
- University of Utah
-
-
-
-
-
Leiden, Holanda, 2333 ZA
- Recrutamento
- Leiden University Medical Center
-
-
-
-
-
Ramat Gan, Israel, 5262000
- Recrutamento
- Sheba Medical Center
-
-
-
-
-
Milan, Itália, 20122
- Recrutamento
- Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano
-
Roma, Itália, 00168
- Recrutamento
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
-
-
-
-
Lodz, Polônia, 93 338
- Recrutamento
- Instytut Centrum Zdrowia Matki Polki
-
Warsaw, Polônia, 01 211
- Recrutamento
- Instytut Matki i Dziecka
-
Warsaw, Polônia, 02 507
- Recrutamento
- Panstwowy Instytut Medyczny MSWiA w Warszawie
-
-
-
-
-
Birmingham, Reino Unido, B15 2TG
- Recrutamento
- Birmingham Women's Hospital
-
Liverpool, Reino Unido, L8 7SS
- Recrutamento
- Liverpool Women's NHS Foundation Trust - Liverpool Women's Hospital
-
London, Reino Unido, W12 0HS
- Recrutamento
- Queen Charlotte's and Chelsea Hospital
-
Oxford, Reino Unido, OX3 9DU
- Recrutamento
- John Radcliffe Hospital
-
-
-
-
-
Graz, Áustria, 8036
- Recrutamento
- Medizinische Universitaet Graz
-
Vienna, Áustria, 1090
- Recrutamento
- Medical University Vienna
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Pregnant and an estimated gestational age (GA) from week 13* to 18 at visit 1
*Randomization for high-risk FNAIT participants to occur at GA Week 12
-
Has a history of greater than or equal to (>=) 1 prior pregnancy with FNAIT based on medical records including: a) neonatal platelet count less than (<) 150*10^9/Liter with no fetal/neonatal intracranial hemorrhage (ICH) or severe fetal/neonatal hemorrhage (standard-risk) OR b) fetus/neonate with ICH or severe hemorrhage in a fetus/neonate (high-risk)
-
Current pregnancy with presence of maternal anti-HPA-1a and/or anti-HPA-5b alloantibody and positive fetal HPA-1a and/or HPA-5b genotype as confirmed by cell-free fetal DNA in maternal blood
-
Health status considered stable by the investigator based on physical examination, medical history, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests performed at screening
-
For maternal participant and neonate/infant, willing to forego participation in another clinical study of an investigational therapy until the last follow-up visit
Exclusion Criteria:
- Currently pregnant with multiple gestations (twins or more)
- History of severe preeclampsia in a previous pregnancy
- History of myocardial infarction, unstable ischemic heart disease, or stroke
- Known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients, to IVIG or to prednisone that would preclude treatment
- Has any confirmed or suspected clinical immunodeficiency syndrome or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm 1: Nipocalimab
Maternal participants with alloantibodies against HPA-1a and/or HPA-5b will be randomized to receive nipocalimab starting at gestational age (GA) week 13 to 18 until before delivery. |
Nipocalimab will be administered intravenously.
Outros nomes:
|
|
Experimental: Arm 2: Intravenous Immunoglobins (IVIG)
Maternal participants with alloantibodies against HPA-1a and/or HPA-5b will be randomized to receive IVIG from GA week 12 for high-risk pregnancies or GA week 20 for standard-risk pregnancies. Additionally, prednisone will be added per study protocol. Participants will be gradually tapered off prednisone after delivery as per investigator judgement or maternal participant tolerance. |
IVIG will be administered intravenously. Prednisone will be administered orally. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fetus/Neonate with Outcome of Death or Adjudicated Severe Bleeding or Platelet Count Less Than (<) 30*10^9/L
Prazo: Up to 1 Week post birth
|
Outcome of fetus/neonate death or adjudicated severe bleeding up to the first week post birth or platelet count <30*10^9/L will be reported. |
Up to 1 Week post birth
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Platelet Count at Birth in a Neonate
Prazo: At birth
|
Platelet count at birth in a neonate will be reported. |
At birth
|
|
Neonate/Fetus with Outcome of Death
Prazo: Up to 1 Week post birth
|
Fetus/neonate with outcome of death will be reported. |
Up to 1 Week post birth
|
|
Neonate with Platelet Count at Birth <10*10^9/L
Prazo: At birth
|
Platelet count at birth <10*10^9/L in a neonate will be reported. |
At birth
|
|
Neonate with Platelet Count at Birth <30*10^9/L
Prazo: At birth
|
Platelet count at birth <30*10^9/L in a neonate will be reported. |
At birth
|
|
Neonate with Platelet Count at Birth <50*10^9/L
Prazo: At birth
|
Platelet count at birth <50*10^9/L in a neonate will be reported. |
At birth
|
|
Neonate with Platelet Count at Birth <150*10^9/L
Prazo: At birth
|
Platelet count at birth <150*10^9/L in a neonate will be reported. |
At birth
|
|
Nadir Platelet Count in a Neonate
Prazo: Up to 1 Week post birth
|
Nadir platelet count in a neonate will be reported. |
Up to 1 Week post birth
|
|
Neonate Requiring Platelet Transfusion
Prazo: Up to 1 Week post birth
|
Neonate who require at least one platelet transfusion will be reported. |
Up to 1 Week post birth
|
|
Number of Platelet Transfusions in Neonate
Prazo: Up to 1 Week post birth
|
Number of platelet transfusions per neonate will be reported. |
Up to 1 Week post birth
|
|
Number of Donor Exposures for Platelet Transfusions in Neonate
Prazo: Up to 1 Week post birth
|
Number of donor exposures for a neonate who received at least one platelet transfusion will be reported. |
Up to 1 Week post birth
|
|
Neonate/Fetus With Adjudicated Bleeding
Prazo: Up to 1 Week post birth
|
Neonate/Fetus with adjudicated bleeding will be reported. |
Up to 1 Week post birth
|
|
Neonate Requiring Postnatal Intravenous Immunoglobulin (IVIG) for the Treatment of Thrombocytopenia
Prazo: Up to 1 Week post birth
|
Neonate requiring IVIG for the treatment of thrombocytopenia will be reported. |
Up to 1 Week post birth
|
|
Maternal Participant with Treatment-Emergent Adverse Events (TEAE), Serious Adverse Events (SAE) and Adverse Event of Special Interest (AESI)
Prazo: Up to Week 24
|
Maternal participant with TEAE, SAE and AESI will be reported. An Adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. |
Up to Week 24
|
|
Maternal Participant with TEAE Leading to Discontinuation of Study Intervention
Prazo: Up to Week 24
|
Maternal participant with TEAE leading to discontinuation of study intervention will be reported. |
Up to Week 24
|
|
Neonate/Infant With TEAE, SAE and AESI
Prazo: From Day of birth to Week 104
|
Neonate/infant with TEAE, SAE and AESI will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. |
From Day of birth to Week 104
|
|
Fetus/Neonate with a TEAE of Bleeding
Prazo: From Day of birth to Week 104
|
Fetus/Neonate with a TEAE of bleeding will be reported. |
From Day of birth to Week 104
|
|
Neonate with a TEAE of Infection
Prazo: From Day of birth to Week 104
|
Neonate with a TEAE of infection will be reported. |
From Day of birth to Week 104
|
|
Bayley Scales Assessment for Infant Development
Prazo: At Week 52 and Week 104
|
The Bayley Scales of infant development is considered the standard assessment of early child development and includes cognition, language, motor skills, social emotional, and adaptive behavior will be reported. The Bayley Scales are reference standards that measure infant and toddler development in five areas: cognition, language, motor skills, social-emotional and adaptive behavior. The cognition, language and motor skills scales are directly administered to the infant, while social-emotional, and adaptive behavior scales are caregiver questionnaires. The scores are standardized using norm reference samples with representative demographics and age adjusted for prematurity. Higher scores in the Bayley Scales indicate better outcomes. |
At Week 52 and Week 104
|
|
Maternal Participants with Incidence of Antibodies to Nipocalimab
Prazo: Up to Week 4
|
Incidence of antibodies to nipocalimab including neutralizing antibodies in maternal serum during pregnancy and postpartum will be reported. |
Up to Week 4
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Citopenia
- Lactente, Recém Nascido, Doenças
- Doenças Hematológicas
- Distúrbios das plaquetas sanguíneas
- Trombocitopenia
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças hemic e linfáticas
- Trombocitopenia Neonatal Aloimune
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Compostos policíclicos
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Pregada
- Pregnas
- Esteróides
- Compostos de anel fundido
- PregadaDiols
- Isotipos de imunoglobulina
- Imunoglobulina G.
- Prednisona
- Imunoglobulinas intravenosas
Outros números de identificação do estudo
- 80202135FNAIT3003
- 2023-509434-19-00 (Identificador de registro: EUCT number)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .